4-[2-(2-Benzyloxycarbonylamino-3-t-butoxy-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester
A 3C-like protease inhibitor.
General information
4-[2-(2-Benzyloxycarbonylamino-3-t-butoxy-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester is an experimental inhibitor of SARS-CoV and SARS-CoV-2 3C-like proteases (Iketani et al., 2021; Yang et al., 2006).
4-[2-(2-Benzyloxycarbonylamino-3-t-butoxy-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester on PubChem
Synonyms
Compound 4
![Structure image - 4-[2-(2-Benzyloxycarbonylamino-3-t-butoxy-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester](/data/images/327.png)
CCOC(=O)C=CC(CC1CCNC1=O)NC(=O)C(CC(C)C)NC(=O)C(C(C)OC(C)(C)C)NC(=O)OCC2=CC=CC=C2
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
3CLpro Crystallization Enzyme assay In vitro In silico |
in silico; in vitro enzyme assay; crystallization; Vero E6 cells; SARS-CoV-2 strain 2019-nCoV/USA_WA1/2020 | 12.12 | The compound inhibited SARS-CoV-2 3C-like protease with an IC50 of ca. 151 nM in an enzyme assay and displayed efficacy against SARS-CoV-2 infection in Vero E6 cells with an EC50 of ca. 2.9 μM. |
Apr/01/2021 |
|
Inhibitors of coronavirus 3CL proteases protect cells from protease-mediated cytotoxicity
3CLpro Small molecule In vitro |
HEK293T cells expressing SARS-CoV-2 3C-like protease | 4.50 | The compound inhibited SARS-CoV-2 3C-like protease with an EC50 of 3.023 µM in vitro. |
Apr/28/2021 |
